CVS Health Corp. continues to fight a civil lawsuit that accuses the corporation and its retail pharmacists of wrongfully ...

One quarter into 2025, CVS Health has risen the most of any stock in the S&P 500, with a share price that has popped 50% ...

In a motion to dismiss most claims, attorneys for the Woonsocket, R.I.-based company argue the DOJ failed to provide key ...

Store closure decisions are based on several factors,” including population shifts and consumer buying patterns, a company ...

The company announced Monday that the MMR vaccine would be available at more than 500 locations of CVS Pharmacy stores and ...

CVS Health is offering measles vaccines to people who live in Pennsylvania after two cases of the disease have been confirmed ...

The healthcare sector, as measured by Health Care Select Sector SPDR Fund (NYSEARCA:XLV), with 12.12% weightage on the S&P ...

Although elevated after 2023 acquisitions, CVS’ financial position remains manageable, in our opinion, and investors should note that CVS intends to maintain a solid investment-grade credit rating.

CVS Health is a BUY. Undervalued with growth potential, it outshines competitors despite sector challenges. See more on CVS ...

In a year marked by macroeconomic uncertainty and renewed trade tensions that have shaken the equity market, CVS Health CVS has emerged as an unexpected outperformer. After a rough 2024, marked by ...

CVS Health CEO David Joyner earned $17.8 million in total compensation in 2024. The company reported compensation data for its six highest-paid executives in its annual proxy report, published April 4 ...

A nurse practitioner who lost her job for declining to prescribe contraceptives has reached a settlement with her former ...